

Emma Boswell Dean

Department of Health Management and Policy
Miami Business School, University of Miami
417-N Jenkins Building, 5250 University Drive
Coral Gables, FL 33146
e:edean@bus.miami.edu | p: 305.284.3903
w: <https://emmabdean.github.io/>

Academic Appointments	<i>Miami Business School, University of Miami</i> Assistant Professor of Health Management and Policy, 2018 - present
Education	<i>The Wharton School, University of Pennsylvania,</i> Ph.D., Managerial Science & Applied Economics; 2018 <i>The Wharton School, University of Pennsylvania,</i> M.S., Managerial Science & Applied Economics; 2015 <i>Cornell University</i> B.S., Biometry & Statistics (Honors); 2008
Interests	Health Economics, Development Economics, Applied Microeconomics
Other Work Experience	<i>The Wharton School, University of Pennsylvania, Philadelphia, PA</i> Research Assistant for Amanda Starc & Robert Town, 2014–2016 <i>Trinity Partners, Waltham, MA</i> Consultant in Market Research & Advanced Analytics, 2010-2013 Associate Consultant in Advanced Analytics, 2008-2009 <i>Ad hoc consulting:</i> Center for Global Development, Médecins Sans Frontières
Publications	Grossman, G., Pierskalla, J. and Dean, E.B. “Government Fragmentation and Public Goods Provision.” <i>Journal of Politics</i> , 2017, 79 (3), pp. 823-840. Dean, E.B., Schilbach, F. and Schofield, H. “Poverty and Cognitive Function.” Chapter in forthcoming NBER book “ <i>The Economics of Asset Accumulation and Poverty Traps</i> ,” Barrett, C.B., Carter, M. and Chavas, J.P. eds.
Other Writing	Berdud, M., Chalkidou, K., Dean, E., Ferraro, J., Garrison, L., Nemzoff, C., and Towse, A. “The Future of Global Health Procurement: Issues Around Pricing Transparency.” OHE Research Paper 18/04.
Working Papers	“ <i>Who Benefits from Pharmaceutical Price Controls? Evidence from India</i> ” With the goal of driving down drug costs, governments across the globe have instituted various forms of pharmaceutical price control policies. Understanding the impacts of such policies is particularly important in low- and middle-income countries, where lack of insurance coverage means that prices can serve as a barrier to access for patients. In this paper, we examine the theoretical and empirical effects of one implementation of pharmaceutical price controls, in which the Indian government placed price ceilings on a set of essential medicines. We find that the legislation

resulted in broadly declining prices amongst both directly-impacted products and competing products. However, the legislation also led to decreased sales of price-controlled and closely related products, preventing trade that would have otherwise occurred. The sales of small, local generics manufacturers were most impacted by the legislation, seeing a 14.5% decrease in market share and a 5.3% decrease in sales. These products tend to be inexpensive, but we use novel data to show that they are also of lower average quality. We provide evidence that the legislation impacted consumer types differentially. The benefits of the legislation were largest for quality-sensitive consumers, while the downsides largely affected poor and rural consumers, two groups already suffering from low access to medicines.

Work in Progress

“Hospital Strategy and the Urban-Rural Divide: Implications for Labor and Delivery” with Ambar La Forgia

“Guilty Until Proven Innocent: Industry Response to Scandal” with Stephen Schwab

“Going Off-Script: Physician License Suspension and the Demand for Prescription Drugs” with Mallick Hossain and Daniel Kaliski

“The Impact of Reduced Pain on Labor Market Outcomes and Cognition Among the Poor” with Sendhil Mullainathan, Frank Schilbach, Heather Schofield, and Anuj Shah

Grant Funding

University of Chicago Trust in India, \$57,000 (with Sendhil Mullainathan, Frank Schilbach, Heather Schofield, and Anuj Shah), 2017

Population Studies Center and Center for Health Incentives and Behavioral Economics, University of Pennsylvania, \$20,000 (with Sendhil Mullainathan, Frank Schilbach, Heather Schofield, and Anuj Shah), 2017

Leonard Davis Institute of Health Economics, \$8,000, 2016

Leonard Davis Institute of Health Economics, \$20,000 (with Sendhil Mullainathan, Frank Schilbach, Heather Schofield, and Anuj Shah), 2016

Global Engagement Fund of the University of Pennsylvania, \$35,000 (with Sendhil Mullainathan, Frank Schilbach, Heather Schofield, and Anuj Shah), 2016

Risk Management and Decision Processes Center, Wharton, \$4,000, 2015

Awards and Fellowships

2017: Judith & William Bollinger Fellowship for Interdisciplinary Research, University of Pennsylvania; George James Travel Award, The Wharton School; Graduate and Professional Student Assembly Travel Award, University of Pennsylvania; Price Theory Camp Attendee, University of Chicago

2016: Fellow, Leonard Davis Institute of Health Economics

2015: Ackoff Fellow, Risk Management and Decision Processes Center, The Wharton School

2014: Research Travel Grant, Center for the Advanced Study of India at University of Pennsylvania; Associated Doctoral Researcher, Indian School of Business at Mohali

Teaching*University of Miami*

Population Health 2018
Undergraduate Course

University of Pennsylvania, Teaching Assistant

Comparative Health Care Systems 2014, 2015, 2017
The Management and Economics of the Pharmaceutical, 2015, 2016
Biotech and Medical Device Industries
Consumers, Firms, and Markets in Developing Countries 2016
Business in the Global Political Environment 2016

**Professional
Activities**

Referee Service: Health Economics, International Journal of Health Economics and Management

Seminar and Conference Presentations:

2018: Center for Global Development, Cornell University, University of Illinois at Chicago, University of Miami, University of Michigan, University of Pennsylvania (Health Policy), Annual Conference of the American Society of Health Economists

2017: International Health Economics Association Conference